Article Synopsis
- The study investigates the link between device-recognized atrial fibrillation (AF) and mortality rates in patients with cardiac implantable devices, focusing on a large data sample from 2015 to 2020.
- Results showed that patients with AF had a significantly higher risk of all-cause mortality (29% increased risk) compared to those without AF, highlighting the seriousness of AF in this population.
- Furthermore, among AF patients, those with nonparoxysmal AF (persistent and permanent) faced even greater mortality risks compared to those with paroxysmal AF, indicating a need for targeted management strategies.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Current estimates of atrial fibrillation (AF)-associated mortality rely on claims- or clinical-derived diagnoses of AF, limit AF to a binary entity, or are confounded by comorbidities. The objective of the present study is to assess the association between device-recognized AF and mortality among patients with cardiac implantable electronic devices capable of sensitive and continuous atrial arrhythmia detection. Secondary outcomes include relative mortality among cohorts with no AF, paroxysmal AF, persistent AF, and permanent AF.
Methods: Using the deidentified Optum Clinformatics US claims database (2015 to 2020) linked to the Medtronic CareLink database, we identified individuals with a cardiac implantable electronic device who transmitted data ≥6 months after implantation. AF burden was assessed during the first 6 months after implantation (baseline period). Subsequent mortality, assessed from claims data, was compared between patients with and without AF, with adjustment for age, geographic region, insurance type, Charlson Comorbidity Index, and implantation year.
Results: Of 21 391 patients (age, 72.9±10.9 years; 56.3% male) analyzed, 7798 (36.5%) had device-recognized AF. During a mean of 22.4±12.9 months (median, 20.1 [12.8-29.7] months) of follow-up, the overall incidence of mortality was 13.5%. Patients with AF had higher adjusted all-cause mortality than patients without AF (hazard ratio, 1.29 [95% CI, 1.20-1.39]; <0.001). Among those with AF, patients with nonparoxysmal AF had the greatest risk of mortality (persistent AF versus paroxysmal AF: hazard ratio, 1.36 [95% CI, 1.18-1.58]; <.001; permanent AF versus paroxysmal AF: hazard ratio, 1.23 [95% CI, 1.14-1.34]; <.001).
Conclusions: After adjustment for potential confounding factors, the presence of AF was associated with higher mortality in our cohort of patients with cardiac implantable electronic devices. Among those with AF, nonparoxysmal AF was associated with the greatest risk of mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286354 | PMC |
| http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In-Hospital Mortality in Children Undergoing Congenital Heart Surgery in North Brazil: A 9-Year Analysis From a Regional Referrel Center.
World J Pediatr Congenit Heart Surg
September 2025
Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas (UFAM), Manaus, Amazonas, Brazil.
To analyze in-hospital mortality in children undergoing congenital heart interventions in the only public referral center in Amazonas, North Brazil, between 2014 and 2022. This retrospective cohort study included 1041 patients undergoing cardiac interventions for congenital heart disease, of whom 135 died during hospitalization. Records were reviewed to obtain demographic, clinical, and surgical data.
View Article and Find Full Text PDFAnalysis of UNOS: Trends in Heart Transplantation for Adults With Congenital Heart Disease in the United States Over 35 Years - A Comparison of Two Eras.
World J Pediatr Congenit Heart Surg
September 2025
Congenital Heart Center, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA.
The purpose of this study is to identify 35-year trends in adult congenital heart disease (ACHD) heart transplant volume, transplant centers, patient characteristics, and longitudinal survival up to ten years. We performed a retrospective review of ACHD patients (≥18 years) who underwent heart transplantation (N = 2,297 transplants) between January 1, 1988, and December 31, 2022, using the United Network for Organ Sharing Database. Trends in transplant volume, transplant centers, patient characteristics, and longitudinal survival were analyzed.
View Article and Find Full Text PDFConcomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Race, Ethnicity, Insurance Payer, and Pediatric Cardiac Arrest Survival.
JAMA Netw Open
September 2025
Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Importance: Lower survival rates among Black adults relative to White adults after in-hospital cardiac arrest are well-described, but these findings have not been consistently replicated in pediatric studies.
Objective: To use a large, national, population-based inpatient database to evaluate the associations between in-hospital mortality in children receiving cardiopulmonary resuscitation (CPR) and patient race or ethnicity, patient insurance status, and the treating hospital's proportion of Black and publicly insured patients.
Design, Setting, And Participants: This retrospective population-based cohort study used the Healthcare Cost and Utilization Project Kids' Inpatient Database (1997-2019 triennial versions).
Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the global burden of disease study 2021.
Int J Surg
September 2025
Department of Gynecology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Background: Ovarian cancer remains the most lethal gynecological cancer, with fewer than 50% of patients surviving more than five years after diagnosis. This study aimed to analyze the global epidemiological trends of ovarian cancer from 1990 to 2021 and also project its prevalence to 2050, providing insights into these evolving patterns and helping health policymakers use healthcare resources more effectively.
Methods: This study comprehensively analyzes the original data related to ovarian cancer from the GBD 2021 database, employing a variety of methods including descriptive analysis, correlation analysis, age-period-cohort (APC) analysis, decomposition analysis, predictive analysis, frontier analysis, and health inequality analysis.